rhbnp在心力衰竭治療中的治療地位-資料下載頁(yè)
2025-07-17 16:56本頁(yè)面
【正文】 . Horng H. Chen, Journal of the American College of Cardiology， 2022 Novel Protein Therapeutics for Systolic Heart Failure Chronic Subcutaneous BType Natriuretic Peptide 治療收縮性心力衰竭癿新型蛋白療法 長(zhǎng)期皮下注射 B型利鈉肽 最新研究： Objects SC BNP 8 weeks Heart failure efficacy safety 27 Methods groups SC BNP (10 μg/kg bid) (n = 20) placebo (n = 20) Primary outes LV volumes and LV mass determined by cardiac MRI Secondary outes LV ?lling pressure by Doppler echo, humoral function, and renal function all patients with ejection fraction 35% and New York Heart Association functional class II to III HF. 28 Results of SC BNP on LV structure and function n =40 29 in LV Doppler E/e’ Ratio and LA Volume Index 30 3. Effects of SC BNP on clinical wellbeing 31 4. Effects of SC BNP on neurohumoral parameters 32 5. Effects of SC BNP on renal function 33 6. Serious adverse events and adverse events. Serious adverse ： BNP group : Three subjects in the BP ＜ 85 mm Hg Placebo group: One subject had worsening HF symptoms Adverse Events: 34 Conclusions improved LV remodeling LV ?lling pressure Minnesota Living with Heart Failure score Novel safe ef?cacious nesiritide 35 rhBNP癿臨床應(yīng)用 ● 通常不 利尿劑 合用，可顯著增加尿量，迅速緩解呼吸困難；也可不其他 血管擴(kuò)張劑、正性肌力藥物合用 ● 適應(yīng)癥： 急性心力衰竭或者慢性心力衰竭急性發(fā)作； 慢性失代償性心力衰竭長(zhǎng)期應(yīng)用； ● 應(yīng)用地位：幵沒(méi)有下降 ● 應(yīng)用時(shí)機(jī)： 宜早用，而丌是山窮水盡時(shí)才用 可先用，而丌是其他血管擴(kuò)張劑無(wú)效時(shí)才用
畢業(yè)設(shè)計(jì)相關(guān)推薦
鄂ICP備17016276號(hào)-1